B+
Bull case
25%
Probability
Target price
$1.60
Analysis reference price unavailable
Analysis 2026-10-25 · RankAlpha Sentiment Codex
PLRX
Pliant TherapeuticsANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$0.90
Analysis reference price unavailable
Analysis 2026-10-25 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$0.40
Analysis reference price unavailable
Analysis 2026-10-25 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-10-25
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+74.2
Score
AI commentary
Cautious monitoring view despite the deterministic positive directional prior: the principal clinical readout remains in 2027, coverage is low, and peer comparability is limited. Pliant announced an October 23 ESMO trial-in-progress poster, not a new efficacy readout. Pliant ESMO announcement No verified recent price reaction or analyst target revisions were available. Zero-valued sentiment fields indicate unavailable measurements, not observed neutral readings.
RankAlpha Sentiment Codex - 2026-10-25
Open full AI memoEvidence flagged
small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report
Impact
tentative
Confidence
-
AI events
2026-12-31eventIntegrin-targeted delivery platform updateHigh impact
Pliant said it planned to provide initial treatment indications and a path forward for its preclinical integrin-targeted siRNA delivery platform in the second half of 2026. A platform update would not itself establish clinical value. [#PR-EARNINGS-2026-08-11] SEC-filed company release
2027-12-31eventFORTIFY interim oncology dataHigh impact
Pliant reported ahead-of-schedule enrollment in the Phase 1b FORTIFY expansion trial of PLN-101095 plus pembrolizumab and expects interim data in 2027. FDA Fast Track designation is supportive of development interactions, not evidence of efficacy or approval. Safety and antitumor activity across the ICI-refractory cohorts remain the decisive tests. [#PR-EARNINGS-2026-08-11] SEC-filed company release Pliant Fast Track announcement
2028-07-01catalystFORTIFY spending and cash runwayHigh impact
Pliant reported $159.6 million of cash, equivalents, and short-term investments at June 30, 2026, and projected funding into the second half of 2028. Trial spending and any financing decision could change that runway and the per-share investment case. [#PR-EARNINGS-2026-08-11] SEC-filed company release
Recommendation
N/A
No formal recommendation provided.
As of 2026-10-25 • Updated nightlySource: Internal modelMethodology